Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients With Hypercholesterolemia and the Metabolic Syndrome (from the VYMET Study)

American Journal of Cardiology

Volumn 103, Issue 12, 2009, Pages 1694-1702

  Robinson, Jennifer G ^a   Ballantyne, Christie M ^b   Grundy, Scott M ^c   Hsueh, Willa A ^d   Parving, Hans Henrik ^e   Rosen, Jeffrey B ^f   Adewale, Adeniyi J ^g   Polis, Adam B ^g   Tomassini, Joanne E ^g   Tershakovec, Andrew M ^g  

^a UNIVERSITY OF IOWA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^e International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^f Clinical Research of South Florida   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; MUSCLE WEAKNESS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PYRROLES; SIMVASTATIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67649397411     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.05.003     Document Type: Article

References (27)

1. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith Jr. S.C., Spertus J.A., and Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112 (2005) 2735-2752
2. Grundy S.M. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 47 (2006) 1093-1100
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
4. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., and Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 44 (2004) 720-732
5. Smith Jr. S.C., Allen J., Blair S.N., Bonow R.O., Brass L.M., Fonarow G.C., Grundy S.M., Hiratzka L., Jones D., Krumholz H.M., Mosca L., Pasternak R.C., Pearson T., Pfeffer M.A., and Taubert K.A. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113 (2006) 2363-2372
6. Brunzell J.D., Davidson M., Furberg C.D., Goldberg R.B., Howard B.V., Stein J.H., and Witztum J.L. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology foundation. Diab Care 31 (2008) 811-822
7. Abate N., Catapano A.L., Ballantyne C.M., Davidson M., Polis A., Smugar S., and Tershakovec A.M. Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: results of two subgroup analyses. J Clin Lipidol 2 (2008) 91-105
8. Deedwania P.C., Hunninghake D.B., Bays H.E., Jones P.H., Cain V.A., and Blasetto J.W. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol 95 (2005) 360-366
9. Denke M., Pearson T., McBride P., Gazzara R.A., Brady W.E., Tomassini J.E., and Tershakovec A.M. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab Vasc Dis Res 3 (2006) 93-102
10. Feldman T., Ose L., Shah A., Zakson M., Meehan A., Johnson-Levonas A., MacCubbin D., Tribble D., Veltri E., and Mitchel Y. Efficacy and safety of ezetimibe/simvastatin versus simvastatin monotherapy in hypercholesterolemic patients with metabolic syndrome. Metab Syndr Relat Disord 5 (2007) 13-21
11. Simons L., Tonkon M., Masana L., Maccubbin D., Shah A., Lee M., and Gumbiner B. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr Med Res Opin 20 (2004) 1437-1445
12. Stalenhoef A.F.H., Ballantyne C.M., Sarti C., Murin J., Tonstad S., Rose H., and Wilpshaar W. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J 26 (2005) 2664-2672
13. Steiner G. Lipid lowering in the patients with prediabetes/metabolic syndrome: what is the evidence?. Curr Opin Lipidol 19 (2008) 585-591
14. Deedwania P., Barter P., Carmena R., Fruchart J.C., Grundy S.M., Haffner S., Kastelein J.J.P., Larosa J.C., Schachner H., Shepherd J., and Waters D.D. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the treating to new targets study. Lancet 368 (2006) 919-928
15. Stender S., Schuster H., Barter P., Watkins C., and Kallend D. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diab Obes Metab 7 (2005) 430-438
16. Vytorin (ezetimibe/simvastatin) [package insert] (2009), Merck/Schering-Plough Pharmaceuticals, North Wales, PA
17. Lipitor (atorvastatin calcium) tablets [package insert] (2009), Parke-Davis, New York
18. Miettinen O., and Nurminen M. Comparative analysis of two rates. Stat Med 4 (1985) 213-226
19. Genest J., Frohlich J., Fodor G., and McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. Can Med Assoc J 69 (2003) 921-924
20. Kastelein J.J.P., van der Steeg W.A., Holme I., Gaffney M., Cater N.B., Barter P., Deedwania P., Olsson A.G., Boekholdt S.M., Demicco D.A., Szarek M., Larosa J.C., Pedersen T.R., and Grundy S.M. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 117 (2008) 3002-3009
21. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon III R.O., Criqui M., Fadl Y.Y., Fortmann S.P., Hong Y., Myers G.L., Rifai N., Smith Jr. S.C., Taubert K., Tracy R.P., and Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
22. Ballantyne C.M., Abate N., Yuan Z., King T.R., and Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 149 (2005) 463-474
23. Conard S.E., Bays H.E., Leiter L.A., Bird S.R., Rubino J., Lowe R.S., Tomassini J.E., and Tershakovec A.M. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol 102 (2008) 1489-1494
24. Goldberg R.B., Guyton J.R., Mazzone T., Weinstock R.S., Polis A., Edwards P., Tomassini J.E., and Tershakovec A.M. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc 81 (2006) 1579-1588
25. Leiter L.A., Bays H., Conard S., Bird S., Rubino J., Hanson M.E., Tomassini J.E., and Tershakovec A.M. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol 102 (2008) 1495-1501
26. Westerbacka J., Corner A., Tiikkainen M., Tamminen M., Vehkavaara S., Hakkinen A.M., Fredriksson J., and Yki-Jarvinen H. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia 47 (2004) 1360-1369
27. Schindhelm R.K., Diamant M., Dekker J.M., Tushuizen M.E., Teerlink T., and Heine R.J. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diab Metab Res Rev 22 (2006) 437-443